Stockreport

Citius Pharmaceuticals Inc (CTXR) Reports Q1 2024 Financials and Progress in Clinical Trials [Yahoo! Finance]

Citius Pharmaceuticals, Inc.  (CTXR) 
NASDAQ:AMEX Investor Relations: ir.citiuspharma.com
PDF Shares Outstanding : As of December 31, 2023, there were 158,966,576 common shares outstanding. R&D Expenses : R&D expenses decreased to $2.6 million in Q1 2024 from [Read more]